lixisenatide (Adlyxin, Lyxumia)
Jump to navigation
Jump to search
Indications
- diabetes mellitus type 2
- may slow progression of Parkinson's disease[3]
- lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months (phase 2 trial)[3]
* in patients with type 2 diabetes & recent acute coronary syndrome, lixisenatide did not significantly affect risk of major cardiovascular events[2]
Dosage
disposable prefilled syringes
Adverse effects
- hypoglycemia
- gastrointestinal: nausea (46%)/vomiting (13%)
- hypersensitivity reactions, including anaphyaxis[1]
Mechanism of action
More general terms
References
- ↑ 1.0 1.1 GLP-1 Agonist Lixisenatide (Adlyxin) Okayed for Type 2 Diabetes in US. Medscape. Jul 28, 2016. http://www.medscape.com/viewarticle/866766
FDA News Release. Jul 28, 2016 FDA approves Adlyxin to treat type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm - ↑ 2.0 2.1 Pfeffer MA, Claggett B, Diaz R et al for the ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26630143
- ↑ 3.0 3.1 3.2 Adam D Diabetes drug slows development of Parkinson's disease. Nature News. April 3, 2024 https://www.nature.com/articles/d41586-024-00974-0
Meissner WG et al Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med 2024;390:1176-1185 Not yet indexed in PubMed https://www.nejm.org/doi/full/10.1056/NEJMoa2312323